Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases

Adeel R. Seyal, Keyur Parekh, Yuri S. Velichko, Riad Salem, Vahid Yaghmai*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Rationale and Objectives: The aim of our study was to evaluate changes in growth kinetics of breast cancer liver metastasis in response to locoregional therapy and compare them to Response Evaluation Criteria in Solid Tumors (RECIST). Materials and Methods: This Health Insurance Portability and Accountability Act-compliant retrospective study was Institutional Review Board approved. Thirty-four chemorefractory breast cancer liver metastases from 21 patients treated with yttrium-90 (90Y) were evaluated. Pre- and posttreatment computed tomography (CT) scans were used to calculate tumor growth kinetics. The growth parameter analyzed was reciprocal of doubling time (RDT). RDT range for stable disease (SD) was defined by the measurement error rate. A negative RDT below the SD range defined response and was categorized as either partial response (PR) or complete response, whereas a positive RDT value above the SD range indicated progressive disease (PD). Comparison was made to tumor response classification according to percentage change in the lesion's maximal diameter per RECIST. Lin's concordance correlation coefficient, Bland-Altman plot, Wilcoxon signed rank test, and Student t test were used for analysis. Significance was set at 0.05. Results: RDT range for SD ranged from -0.46 to +2.17. Six lesions with PR based on RECIST showed PR based on their volumetric growth rate (mean RDT of -17.3±2.6). Similarly, one lesion with PD according to RECIST was categorized as PD based on its growth kinetics (RDT of 10.2). However, 14 (51.85%) lesions classified as SD by RECIST had PR according to growth kinetics (mean RDT of -7.8), six (22.22%) lesions were categorized as SD (mean RDT of 0.8), whereas seven (25.93%) lesions showed PD (mean RDT of 4.5). Growth kinetic parameters were significantly different for lesions with PR when compared to lesions with PD (P<.0001). Conclusions: In patients with breast cancer liver metastases undergoing locoregional therapy, RECIST categorization may not be an accurate reflection of treatment response.

Original languageEnglish (US)
Pages (from-to)950-957
Number of pages8
JournalAcademic radiology
Issue number8
StatePublished - Aug 2014


  • Breast neoplasm
  • Computed tomography
  • Liver metastasis
  • Yttrium-90

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases'. Together they form a unique fingerprint.

Cite this